|
Postdoctoral Researcher
Federal University of Minas Gerais (UFMG), Brazil
Email: camilasimoesf@gmail.com
VALIDATE Role:
Network Management Board 2025+, VALIDATE Fellow 2025-2027, Network Associate
Research Keywords:
Leishmaniasis, Treatment, Vaccines, Diagnostics, Animal Models
Biography:
Dr. Camila Simões de Freitas is a Postdoctoral Researcher at the Federal University of Minas Gerais (UFMG), Brazil, with a PhD in Infectious Diseases and Tropical Medicine. Her research focuses on vaccine development, diagnostics, and therapeutics for neglected tropical diseases, particularly leishmaniasis. Her expertise includes cell culture, in vitro and in vivo infections, molecular biology, and immunological assays, essential for understanding host-pathogen interactions and novel control strategies. With international research experience, she is committed to translational science and strengthening vaccine and diagnostic R&D in low-resource settings.
Related Websites:
ResearchGate
LinkedIn
Key Publications:
- Freitas, C. S., Câmara, R. S. B., et al. Urine and serum-based ELISA using a recombinant protein and synthetic peptide for the diagnosis of tegumentary leishmaniasis, Diagnostic Microbiology and Infectious Disease, Volume 111, Issue 3, 2025, 116631, ISSN 0732-8893. https://doi.org/10.1016/j.diagmicrobio.2024.116631
- Freitas, C. S.; PEREIRA, ISABELA A.G. ; et al. New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasis. CYTOKINE, v. 177, p. 156543, 2024. https://doi.org/10.1016/j.cyto.2024.156543
- Freitas, C. S., Lage, D. P., Machado, A. S., et al. Exploring drug repositioning for leishmaniasis treatment: Ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasis. Cytokine, volume 164 (2023). https://doi.org/10.1016/j.cyto.2023.156143
- Freitas, C. S., Santiago, S. S., Lage, D. P., et al. In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis. Experimental Parasitology, volume 251 (2023). https://doi.org/10.1016/j.exppara.2023.108555
- Freitas, C.S., Oliveira-da-Silva, J.A., Lage, D.P. et al. Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis. Parasitol Res 120, 321–335 (2021). https://doi.org/10.1007/s00436-020-06971-2
- Freitas CS, Lage DP, Oliveira-da-Silva JA, Costa RR, et. al. In vitro and in vivo antileishmanial activity of b-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis. Parasite 28, 38 (2021). DOI: 10.1051/parasite/2021036
|
